Cargando…

Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)

BACKGROUND: Cachexia, described as weight loss (mainly in lean body mass [LBM]) and anorexia, is common in patients with advanced cancer. This study examined the efficacy and safety of anamorelin (ONO‐7643), a novel selective ghrelin receptor agonist, in Japanese cancer patients with cachexia. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katakami, Nobuyuki, Uchino, Junji, Yokoyama, Takuma, Naito, Tateaki, Kondo, Masashi, Yamada, Kouzo, Kitajima, Hiromoto, Yoshimori, Kozo, Sato, Kazuhiro, Saito, Hiroshi, Aoe, Keisuke, Tsuji, Tetsuya, Takiguchi, Yuichi, Takayama, Koichi, Komura, Naoyuki, Takiguchi, Toru, Eguchi, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814824/ https://www.ncbi.nlm.nih.gov/pubmed/29205286 http://dx.doi.org/10.1002/cncr.31128

Ejemplares similares

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial
por: Takayama, Koichi, et al.
Publicado: (2016)

A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia
por: Hamauchi, Satoshi, et al.
Publicado: (2019)

A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index
por: Naito, Tateaki, et al.
Publicado: (2022)

Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile
por: Pietra, Claudio, et al.
Publicado: (2014)

Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model
por: Northrup, R., et al.
Publicado: (2013)

Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study
por: Takayama, Koichi, et al.
Publicado: (2022)

Effects of the Cathepsin K Inhibitor ONO-5334 and Concomitant Use of ONO-5334 with Methotrexate on Collagen-Induced Arthritis in Cynomolgus Monkeys
por: Yamada, Hiroyuki, et al.
Publicado: (2019)

Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies
por: Horinouchi, Hidehito, et al.
Publicado: (2019)

Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies
por: Saka, Hideo, et al.
Publicado: (2020)

Synthesis and Applications of (ONO Pincer)Ruthenium‐Complex‐Bound Norvalines
por: Isozaki, Katsuhiro, et al.
Publicado: (2016)

Death and Emergency Readmission of Infants Discharged After Interventions for Congenital Heart Disease: A National Study of 7643 Infants to Inform Service Improvement
por: Crowe, Sonya, et al.
Publicado: (2016)

Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients—Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study
por: Takayama, Koichi, et al.
Publicado: (2016)

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
por: Wu, Jingjing, et al.
Publicado: (2016)

Fabrication of a double-sided silicon microstrip detector with an ONO capacitor dielectric film
por: Saitô, Y, et al.
Publicado: (1995)

ONO-AE3-208 inhibits myeloid derived suppressor cells and glioma growth
por: Kohanbash, Gary, et al.
Publicado: (2014)

Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease
por: Nomoto, Masahiro, et al.
Publicado: (2018)

Bimetallic iron–iron and iron–zinc complexes of the redox-active ONO pincer ligand
por: Wong, Janice L., et al.
Publicado: (2016)

Correction: Ono, K. Calibration Methods of Acoustic Emission Sensors. Materials 2016, 9, 508
por: Ono, Kanji
Publicado: (2016)

Thicker polyethylene inserts (≥ 13 mm) increase the risk for early failure after primary cruciate-retaining total knee arthroplasty (TKA): a single-centre study of 7643 TKAs
por: Rajamäki, Anni, et al.
Publicado: (2022)

Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement
por: Yu, Helen, et al.
Publicado: (2018)

Germanium Complexes with ONO Tridentate Ligands: O-H Bond Activation Control According to DFT Calculations
por: Zaitsev, Kirill V., et al.
Publicado: (2023)

Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model
por: Hanada, Kako, et al.
Publicado: (2022)

Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia
por: Tsukiyama, Ikuto, et al.
Publicado: (2023)

Randomised clinical trial: exploratory phase 2 study of ONO‐2952 in diarrhoea‐predominant irritable bowel syndrome
por: Whitehead, W. E., et al.
Publicado: (2016)

A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia
por: Sekiguchi, Naohiro, et al.
Publicado: (2020)

Evidence for partial pharmaceutical reversal of the cancer anorexia–cachexia syndrome: the case of anamorelin
por: Anker, Stefan D, et al.
Publicado: (2015)

Phase I study of tirabrutinib (ONO‐4059/GS‐4059) in patients with relapsed or refractory B‐cell malignancies in Japan
por: Munakata, Wataru, et al.
Publicado: (2019)

ONO‐7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first‐in‐human study
por: Beale, Dominic, et al.
Publicado: (2021)

First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors
por: Iwasa, Satoru, et al.
Publicado: (2022)

Anamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy
por: Graf, Solomon A, et al.
Publicado: (2017)

Studies on Some Biologically Cobalt(II), Copper(II) and Zinc(II) Complexes With ONO, NNO and SNO Donor Pyrazinoylhydrazine-Derived Ligands
por: Chohan, Zahid H., et al.
Publicado: (1998)

Single injection of sustained-release prostacyclin analog ONO-1301-MS ameliorates hypoxic toxicity in the murine model of amyotrophic lateral sclerosis
por: Tada, Satoru, et al.
Publicado: (2019)

Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07)
por: Satoh, Taroh, et al.
Publicado: (2021)

Initial Thermal Decomposition Mechanism of (NH(2))(2)C=C(NO(2))(ONO) Revealed by Double-Hybrid Density Functional Calculations
por: Guan, Yulei, et al.
Publicado: (2021)

Oncology Update: Anamorelin
por: Prommer, Eric
Publicado: (2017)

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
por: Callahan, Margaret K, et al.
Publicado: (2013)

Highly Selective Molybdenum ONO Pincer Complex Initiates the Living Ring-Opening Metathesis Polymerization of Strained Alkynes with Exceptionally Low Polydispersity Indices
por: Bellone, Donatela E., et al.
Publicado: (2014)

Responses to the Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines
por: Kozaki, Ryohei, et al.
Publicado: (2018)

Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis
por: Tanaka, Makoto, et al.
Publicado: (2017)

Innovative therapeutic strategy using prostaglandin I(2) agonist (ONO1301) combined with nano drug delivery system for pulmonary arterial hypertension
por: Kanaya, Tomomitsu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vnpt77d8trc74nq6lfci8ouniu